NRF2 expression significantly correlated with drug sensitivity in multiple ER-positive breast cancer cell lines, but not associated with pathological complete response after neoadjuvant chemotherapy in breast cancer patients regardless of subtypes. Here, NFE2L2 is linked to breast carcinoma.